|
＞
|
2009
|
Start up AcaHealth Pharma & Biotech Company.
|
|
＞
|
2011
|
Set up pilot plant for purification of AH-101-CVD from a anti-aging Chinese herb as chemical drug development.
|
|
＞
|
2012
|
Pilot plant finished, started the process with SOP with GMP ccompliance.
|
|
＞
|
2013
|
Development the crystallization technology for AH-101-CVD in Kg level (99.67% pure) in 2013.
|
|
＞
|
2014
|
Commissioned to CRO for the genotoxicity of AH-101-CVD up to 5g/Kg in mice without any toxicity.
|
|
＞
|
2015
|
Commissioned to CRO for the 3 months repeated dose toxicology up to 2.5g/Kg in rat without any toxicity.
|
|
＞
|
2016
|
AcaHealth granted a SBIR to support the safety pharmacology including beagle dog.
|
|
＞
|
2016
|
Finished safety pharmacology including beagle dog without any harmful effect in 2016.
|
|
＞
|
2017
|
Purchased 3 factories for AcaHealth company in June 2017.
|
|
＞
|
2018
|
Established Research Center and New herbal Industrial & Cultural Hall.
|
|
＞
|
2018
|
Commissioned to CRO for the 3 months repeated dose toxicology up to 640mg/Kg in beagle dog without any toxicity.
|
|
＞
|
2018
|
A US material patent (AH-101-CVD derivatives) for unmet medical need was granted on 06/26/2018.
|
|
＞
|
2018
|
Submitted IND to US FDA in Sep.
|
|
＞
|
2020
|
Granted IND from US FDA in Jan 23.
|
|
＞
|
2020
|
Granted IND from Taiwan FDA in Oct.
|
|
＞
|
2021
|
We are on-going phase 1 clinical trial in Taipei Medical University Hospitals in 2021 July.
|